TITLE:
Study of TRM-1 (TRAIL-R1 Monoclonal Antibody) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)

CONDITION:
Lymphoma, Non-Hodgkin

INTERVENTION:
TRAIL-R1 mAb (TRM-1; HGS-ETR1)

SUMMARY:

      The purpose of this study is to evaluate the safety, efficacy and exposure to TRM-1 in
      subjects with relapsed or refractory Non-Hodgkin's Lymphoma (NHL).
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Primary Inclusion Criteria:

          -  Relapsed or refractory histologically confirmed Non-Hodgkin's Lymphoma

          -  Previously treated with at least 1 therapeutic regimen and relapsed or progressed or
             failed to achieve a response after the last regimen

          -  18 years of age or older

        Primary Exclusion Criteria:

          -  Received a non-FDA approved investigational agent within the last 4 weeks

          -  Received cancer therapies (chemotherapy, biological therapy [including
             hormonotherapy], radiation therapy or immunosuppressants within the last 3 weeks, 8
             weeks for monoclonal antibodies, radioimmunotherapy or nitrosourea

          -  Eligible for a hematopoietic stem cell transplant (HSCT) or have had an autologous
             HSCT within the last 16 weeks

          -  Prior history of an allogeneic HSCT

          -  HIV, AIDS-related lymphoma, central nervous system (CNS) lymphoma, Hepatitis-B or
             Hepatitis-C

          -  Infection requiring antibiotics within the last 4 weeks

          -  Major surgery within the last 4 weeks

          -  Pregnant or breast-feeding women

          -  History of other cancers within the past 5 years
      
